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Summary
Human melanomas exhibit relatively high somatic mutation burden compared to other malignancies. These somatic mutations may produce neoantigens that are recognized by the immune system, leading to an antitumor response. By irradiating a parental mouse melanoma cell line carrying three driver mutations with UVB and expanding a single-cell clone, we generated a mutagenized model that exhibits high somatic muta- 
K E Y W O R D S
Braf, immunotherapy, melanoma, mouse models, UV radiation exome (Cancer Genome Atlas, 2015) . The vast majority of these are UV signature mutations, most of which are thought to be passenger mutations rather than driver gene changes that promote a selective growth advantage (Vogelstein et al., 2013) . However, these mutations have the potential to act as neoantigens and elicit antitumor immune responses. Indeed, high somatic mutation burden in melanoma has been reported to be associated with improved survival in the setting of immune checkpoint blockade (Snyder et al., 2014; Van Allen et al., 2015) . The success of a phase 2 clinical trial using PD-1 blockade to treat mismatch repair-deficient colorectal and non-colorectal cancers further supports this hypothesis (Le et al., 2015) .
In melanoma, ultraviolet radiation is significantly involved in the accumulation of somatic mutations and the pathogenesis of the malignancy. Recent studies corroborate the role of ultraviolet radiation in all evolutionary stages of melanoma (Martincorena et al., 2015; Shain et al., 2015) . The number of mutations correlates with cumulative sun exposure inferred from age and anatomical site and with histological features of sun exposure including solar elastosis (Shain et al., 2015) . We have recently reported the generation of the YUMM (Yale University Mouse Melanoma) cell lines, which are derived from various genetically engineered mouse models of melanoma with human-relevant driver mutations (Meeth, Wang, Micevic, Damsky, & Bosenberg, 2016 
| RESULTS
The YUMM cell lines including YUMM1.7 have been previously described, are distributed by the American Type Culture Collection (ATCC), and are widely used (Ho et al., 2015; Homet Moreno et al., 2016; Meeth et al., 2016; Scortegagna et al., 2015) . Briefly, the A large proportion of these single-base changes (81.5%) were C>T transitions, which is consistent with ultraviolet light treatment and mutagenesis ( Figure 1b) . To assess the stability of the mutations in culture, four mutations unique to YUMMER1.7 and not detected in YUMM1.7 were evaluated in early and late passages of YUMMER1.7.
All four mutations were detected in both passage 15 and passage 25 of YUMMER1.7 ( Figure S1 ). Upon evaluation of DNA content in the cell lines, it was determined that YUMM1.7 contains both diploid and tetraploid clones, whereas YUMMER1.7 is tetraploid with twice the DNA content as splenocytes ( Figure S2a ). The allele frequencies of YUMMER1.7 mutations compared to C57BL/6J background center around 0.25, further supporting that YUMMER1.7 is a tetraploid clone ( Figure S2b ).
Significance
Mouse models of melanoma that accurately recapitulate the driver mutations as well as the somatic mutation burden present in the human disease can be used to advance our understanding of melanoma and its response to therapy.
Here, we describe a novel mouse melanoma model, YUMMER1.7, which reflects the genomic features of human melanoma and elicits a functional antitumor immune response in immunocompetent C57BL/6J hosts. As this model is responsive to immune checkpoint inhibitors including anti-CTLA-4 and anti-PD-1, we anticipate that it will serve as a useful preclinical resource to evaluate new immunotherapies.
To understand in vivo growth characteristics of YUMMER1.7 relative to YUMM1.7, we subcutaneously implanted 100,000 cells of each model into the flanks of C57BL/6J mice and measured tumor volume over time. As expected, all YUMM1.7 tumors exhibited rapid and continuous growth ( Figure 1c ). In contrast, YUMMER1.7 cells initially grew to a palpable tumor of approximately 10-50 mm 3 followed by striking tumor regression without regrowth. Regression occurred in approximately 80% of YUMMER1.7 tumors following 100,000 cell injections and was even more consistently observed following 50,000 and 10,000 cell injections ( Figure S3 ). Clinical regression of YUMMER1.7 melanomas (tumor volume decrease) was observed as early as 14 days postinjection, and complete regression was durable for at least 120 days.
Next, we implanted greater numbers of YUMMER1.7 cells in a similar fashion. In contrast to the 100,000 cell injections, the inocu- when 100,000 cells were injected ( Figure 1f ). We found that depletion of both CD4 and CD8 T cells significantly accelerated tumor growth compared to the isotype control (p = .006). These results suggested that tumor regression was the result of an adaptive immune response involving both CD4 and CD8 T cells. Subsequently, we explored whether mice that had rejected 100,000 cell YUMMER1.7 tumors would develop immunity against higher doses of YUMMER1.7 tumors ( Figure S4 ). We injected 100,000 YUMMER1.7 cells into the right flanks of C57BL/6J mice and allowed tumors to completely regress after 30 days.
This cohort was then rechallenged with 500,000 cell YUMMER1.7
(I + YUMMER1.7) or 500,000 cell YUMM1. 
| DISCUSSION
Mouse models of cancer have been a tremendous resource for studying the pathophysiology of human malignancies and have provided preclinical rationale for novel therapies (Day, Merlino, & Van Dyke, 2015) . However, low somatic mutation burden in many mouse models can limit tumor immune responses and the study of immunotherapy, demonstrating a need for immunogenic models (Ward, Gubin, & Schreiber, 2016) . As reported previously, YUMM1.7 exhibits similar that offset tyrosine and serine/threonine kinase signals induced by the T cell receptor (Topalian, Drake, & Pardoll, 2015) . In addition, it also outcompetes CD28 for its ligands, CD80 and CD86, preventing adequate co-stimulation of naïve T cells (Pardoll, 2012) . We anticipate that YUMMER1.7 will serve as an immunogenic mouse melanoma model for the scientific community and as a valuable addition to the YUMM series. It illustrates the role that antigen burden plays in dictating the extent of the antitumor immune response and offers the opportunity to study the immune microenvironment with the goal of evaluating drugs in preclinical stages and developing novel immune therapeutics. Finally, the described approach used to enhance immunogenicity of the YUMM1.7 line can also be applied to other syngeneic mouse models of cancer.
| METHODS

| Celllinesandtissueculture
YUMMER1.7 was derived from YUMM1.7, which was generated from a cutaneous mouse melanoma containing the alleles Braf V600E , Meeth et al., 2016) . Irradiation of YUMM1.7 included three rounds of 1,500 J/m 2 UVB (3 W for 500 s) when cells were 50%-70% confluent. Cells were given time to recover and proliferate before being replated and proceeding to the next UV treatment. After the final UV treatment, a single cell was clonally expanded. YUMM1.7 and YUMMER1.7 DNA contents were assessed using a Propidium Iodide Flow Cytometry Kit according to the manufacturer's instructions (Abcam, Cambridge, UK). YUMMER1.7-GFP and YUMM1.7-GFP were generated using a P-YUK-GFP plasmid with PiggyBac Transposase Expression Vector, a gift from Tian Xu, Department of Genetics, Yale University. Transfection was performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA), and cells were selected using blastomycin resistance. All cell lines were maintained in DMEM/F12 media containing 10% FBS, 1% non-essential amino acids and 1% penicillin-streptomycin.
| Invivomousestudies
Four-to six-week-old C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and allowed to acclimate for 1 week prior to use. C57BL/6J Rag1 −/− mice were also obtained from the Jackson Laboratory and maintained in our mouse colony.
All animal experiment protocols were followed according to 
| Histologicalanalysis
At least three tumors were fixed in 10% formalin for each condition-100,000 cell YUMM1.7-GFP, 100,000 cell YUMMER1.7-GFP, and 500,000 cell YUMMER1.7-GFP tumors at every time point-and embedded in paraffin. Cut sections were stained using GFP ( LLC., Ashland, OR). Antibodies against CD45 (A20), CD8 (53-6.7), and CD3 (145-2C11) were purchased from eBioscience. The antibodies against CD4 (RM4-5), PD-1 (RMP1-14), and TIGIT (1G9) were purchased from BioLegend.
| Statisticalanalyses
Unpaired two-tailed t tests and Kaplan-Meier statistical analyses were performed using GrAphpAd prism (version 6.0a for Mac OS X;
GraphPad Software, La Jolla, CA) using a significance cutoff: MarkDuplicates. The resulting alignments were subjected to base quality score recalibration in GATK 3.6 using the Mus muscularis C57BL/6J SNP and Indel databases according to GATK best practices.
Variants unique to YUMMER1.7 compared to YUMM1.7 or cell lines compared to wild-type C57BL/6J were called using GATK MuTect2 with the above-mentioned dbsnp and mm10 references and were selected for downstream analysis if they passed the default MuTect2 filters. Then, variants were annotated using Annovar (February 01, 2016 release) with the corresponding mm10 ensGene reference according to the program manual.
| Sangersequencing
Four genomic loci that exhibited mutations in YUMMER1.7 but not in YUMM1.7 based on exome sequencing were Sanger-sequenced from different passages of YUMMER1.7 in vitro. Primers amplifying these loci with 200-to 500-bp flanks were designed using default parameters in Primer-BLAST (NCBI, https://www.ncbi.nlm.nih.
gov/tools/primer-blast/) and checked for specificity to the Mus musculus genome. PCR reactions using these primers and YUMMER1.7 genomic DNA were conducted, and PCR products were purified using QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Sanger sequencing reactions were performed by Genewiz (South Plainfield, NJ), and chromatograms were visualized with 4Peaks (http://nucleobytes.com/4peaks/).
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